Test Catalog

Test ID: FPPCA    
PCA3 (Prostate Cancer Antigen 3)

Method Description Describes how the test is performed and provides a method-specific reference

The PCA3 test is a molecular assay that detects the mRNA of the DD3 gene expressed in prostate cells.  The cells are obtained from patient urine samples after digital rectal exam (DRE). The PCA3 test is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. In recent studies it was shown to have a specificity of 78% and a sensitivity of 57% in cancer vs. non-cancer.  This test was approved by FDA in February 2012 to aid in the decision for a repeat biopsy.

PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Monday, Wednesday, Friday

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

4 - 7 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Clinic Laboratories until the release of the test result

6 - 9 days

Performing Laboratory Location Indicates the location of the laboratory that performs the test

University of Michigan (MLabs)